Skip to content

Proton radiation versus carbon ion radiation for refractory pituitary adenoma: prospective phase II trial

Proton radiation versus carbon ion radiation for refractory pituitary adenoma: prospective phase II trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035502
Enrollment
Unknown
Registered
2020-08-13
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory pituitary adenoma

Interventions

A:Carbon Ion Radiation (60GyE/20Fx)
B:Proton Radiation (60GyE/30Fx)

Sponsors

Shanghai Proton and Heavy Ion Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-80 years; 2. Histologically confirmed pituitary adenoma; 3. High risk of refractory tumor: (1) Aggressive growth of tumor after one or more operation, and difficult to be completeby removed with re-resection; (2) Rapid growth (tumor volume increassion more than 5% in 3-6 months); (3) For the first treatment, the tumor showed aggressive growth and large size, Ki67 above 3%; (4) Pathology included one of five types of "high-risk pituitary adenomas" : sparsely granular growth hormone cell adenomas, male prolactin cell adenomas, polyhormone Pit-1 positive adenomas, silent ACTH cell adenomas, and Crooke cell adenomas. 4. Residual lesion detected in imaging studies; 5. No distant and/or spinal metastasis; 6. Karnofsky Performance Score >=60; 7. Written informed consent (made available with required signature prior to enrollment on trial and initiation of treatment).

Exclusion criteria

Exclusion criteria: 1. Completely resection of pituitary lesion; 2. Distant metastatis; 3. Prior treatment with interstitial radioactive seeds; 4. Known carcinoma (excluding basal cell carcinoma,squamous cell carcinoma of the skin); 5. Pregnant or lactating women; 6. Inability of subject to understand character and individual consequences of the clinical trial.

Design outcomes

Primary

MeasureTime frame
Progression-free Survival;

Secondary

MeasureTime frame
Overall Survival;Side Effect;

Countries

China

Contacts

Public ContactLin Kong

Shanghai Proton and Heavy Ion Center

lin.kong@sphic.org.cn+86 021-38296666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026